Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Pancreatic Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 1Resectable Pancreatic Carcinoma 1Resectable Pancreatic Cancer 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1Advanced Pancreatic Cancer 1Adenocarcinoma of the Pancreas 1Adenocarcinoma 1

Interventions

Cyclophosphamide 23fludarabine phosphate 20Cyclosporine 19Busulfan 17Peripheral Blood Stem Cell Transplantation 14Mycophenolic Acid 14Antilymphocyte Serum 13Whole-Body Irradiation 12Radiotherapy 11Cord Blood Stem Cell Transplantation 10Methotrexate 9Filgrastim 9Methylprednisolone 8Cytarabine 6sargramostim 5Tacrolimus 5Melphalan 5Etoposide 5Cyclosporins 4merphos 3fludarabine 3Transplantation 3Thiotepa 3Granulocyte Colony-Stimulating Factor 3Decitabine 3bryostatin 1 2aldesleukin 2Topotecan 2Thioguanine 2Thalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Anemia, Refractory × paricalcitol × Clear all
NCT00064376 2018-01-29

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Cedars-Sinai Medical Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡